Abstract
. Antineoplastic drug regimens used in the 46 pediatric recent gastrointestinal or urinary disturbances had occurred, patients with solid tumours included in the present study and diets as well as appetites were normal.
Cisplatin was administered as a short (1 h) intravenous infusion after a 2 h fluid overload with a glucosaline solution Patients treated with cisplatin (n=17) (sodium concentration from 51 to 77 mmol/l ) at the rate of 125 ml/m2 hourly. Over the next 21 given age and sex) for current height were calculated using growth charts [13] . The glomerular filtration rate (GFR) median period of 7.1 years. The remaining 29 patients The age at diagnosis had ranged from 2 weeks to 16 years had neuroblastomas (n=19), germ cell tumours (n= (median 10 months). All patients had normal plasma creatin-5), liver tumours (n=2), brain tumours (n=2) and ine at diagnosis. None of them had undergone renal surgery one a bone tumour. The 46 patients had been treated or renal X-ray during therapy. None of the patients had with the antineoplastic combinations given in Table 1 presented any episode of acute renal failure related to the and had been off antineoplastic agents for a median chemotherapy, defined as a plasma creatinine increase of period of 9.8 years.
>50 mmol/l.
The results of the study are shown in Table 2 . The
At the time of our study, the patients were disease-free and off antineoplastic medication for at least 3 years. No age at diagnosis was significantly greater in patients treated with cisplatin (4.9, from 0.14 to 16 years) than creatinine equation (r2 s =0.164) or circulating magnesium (r2 s =0.012). In addition, no significant correlation in those without (0.8, from 0.04 to 16 years). The majority of patients treated without cisplatin were was noted between the treatment-free period and circulating creatinine (r2 s =0.0018), GFR estimated by the male. At the time of the study, the age and the body weight were similar in the three study groups. Patients height/creatinine equation (r2 s =0.039) or circulating magnesium (r2 s =0.0071). who had not been treated with cisplatin were shorter in stature than those who had been treated with this agent. The height was similar in the two groups of Discussion patients when expressed as Z-score after correction for age and sex. Plasma creatinine was slightly but significantly higher by~10 mmol/l, and the GFR estimated These data demonstrate mild permanent renal disturbances in subjects who had been treated during infancy from the height/creatinine equation was lower bỹ 10 ml (min/1.73 m2) in patients treated with cisplatin or childhood with cisplatin because of malignancies. The disturbances include both reduced GFR and hypoas compared with the patients who had received treatment other than cisplatin and the control sub-magnesaemia. On the other hand, our study protocol revealed no persistent renal abnormality in subjects jects. Plasma creatinine was >100 mmol/l (102 and 104 mmol/l respectively) in two of the 17 patients with the same malignancies who had been treated with an antineoplastic combination that did not include treated with cisplatin. The circulating magnesium showed a slight but significantly lowered concentration cisplatin.
Apart from cisplatin, chemotherapeutic agents used by~0.03 mmol/l in the group of patients treated with cisplatin. This parameter was <0.75 mmol/l (0.67 and in the present groups of patients that have been associated with renal toxicity comprise methotrexate, 0.73 mmol/l ) in two of the patients treated with cisplatin. Sitting blood pressure and heart rate, plasma and cyclophosphamide, vincristine and especially ifosfamide [5,6 ]. These antineoplastic agents had been used in urinary calcium, plasma phosphate and the maximal tubular reabsorption of phosphate were not statistically both patient groups. The fact that the group of patients treated without cisplatin showed no persisting renal different in the three study groups. The urinalysis showed no pathological leucocyturia, erythrocyturia, sequelae prompts us to suggest that methotrexate, cyclophosphamide and vincristine either do not cause proteinuria or glucosuria either in the 46 patients or in the 20 control subjects. permanent renal disturbances, or cause permanent renal damage only if given in association with cisplatin. In patients treated with cisplatin, no significant correlation was observed between individual cumulat-Signs of tubular dysfunction including glucosuria, aminoaciduria, hypophosphataemia, hypokalaemia and ive doses of this antineoplastic agent and circulating creatinine (r2 s =0.095), GFR estimated from the height/ metabolic acidosis sometimes occur after ifosfamide
